Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
Methods and analysis In this placebo-controlled, double-blind, phase III trial, patients are being randomised in a 1:1:1 ratio to receive 9 mg or 18 mg of BI 1015550 or placebo two times per day over at least 52 weeks, stratified by use of background antifibrotics (nintedanib/pirfenidone vs neither)...
Main Authors: | Toby M Maher, Michael Kreuter, Vincent Cottin, Susanne Stowasser, Marlies S Wijsenbeek, Yi Liu, Fernando J Martinez, Luca Richeldi, Arata Azuma, Justin M Oldham, Claudia Valenzuela, Maud Gordat, Donald F Zoz |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | BMJ Open Respiratory Research |
Online Access: | https://bmjopenrespres.bmj.com/content/10/1/e001563.full |
Similar Items
-
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
by: Toby M Maher, et al.
Published: (2023-12-01) -
Plain language summary: clinical trial of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
by: Luca Richeldi, et al.
Published: (2022-12-01) -
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
by: Toby M. Maher, et al.
Published: (2022-10-01) -
Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment
by: Vincent Cottin, et al.
Published: (2014-03-01) -
BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
by: Franziska Elena Herrmann, et al.
Published: (2022-04-01)